Passage BIO (PASG) Amortizatization of Intangibles (2020 - 2025)
Passage BIO (PASG) posted quarterly Amortizatization of Intangibles of $129000.0 for Q1 2025, up 129.05% year-over-year from $56318.6 in Q1 2024, and up 135.34% quarter-over-quarter from -$365000.0 in Q4 2024.
Passage BIO (PASG) Amortizatization of Intangibles (2020 - 2025) Analysis & Trends
Passage BIO's Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $129000.0 for Q1 2025.
- In Q1 2025, Amortizatization of Intangibles rose 129.05% year-over-year to $129000.0; the TTM figure through Dec 2025 stood at $129000.0 (up 108.45% YoY), while the FY2025 annual figure was $129000.0, up 108.45% from the prior year.
- Amortizatization of Intangibles for Q1 2025 stood at $129000.0, up from -$365000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $889000.0 in Q3 2021, with the low at -$848000.0 in Q4 2023.
- The 5-year median for Amortizatization of Intangibles is -$98000.0 (2023), against an average of $6882.4.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles tumbled 680.0% in 2023, then jumped 129.05% in 2025.
- Passage BIO's Amortizatization of Intangibles stood at $543000.0 in 2021, then sank by 179.74% to -$433000.0 in 2022, then sank by 95.84% to -$848000.0 in 2023, then surged by 56.96% to -$365000.0 in 2024, then surged by 135.34% to $129000.0 in 2025.
- Business Quant data shows PASG's Amortizatization of Intangibles at $129000.0 in Q1 2025, -$365000.0 in Q4 2024, and -$421000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 129,000.00 |
| Mar 31, 2025 | 129,000.00 |
| Dec 31, 2024 | -365,000.00 |
| Dec 31, 2024 | -365,000.00 |
| Sep 30, 2024 | -421,000.00 |
| Sep 30, 2024 | -421,000.00 |
| Jun 30, 2024 | -297,000.00 |
| Jun 30, 2024 | -297,000.00 |
| Mar 31, 2024 | -444,000.00 |
| Mar 31, 2024 | -444,000.00 |
| Dec 31, 2023 | -848,000.00 |
| Dec 31, 2023 | -848,000.00 |
| Sep 30, 2023 | -319,000.00 |
| Sep 30, 2023 | -319,000.00 |
| Jun 30, 2023 | -771,000.00 |
| Jun 30, 2023 | -771,000.00 |
| Mar 31, 2023 | -98,000.00 |
| Mar 31, 2023 | -98,000.00 |
| Dec 31, 2022 | -433,000.00 |
| Dec 31, 2022 | -433,000.00 |